XML 28 R14.htm IDEA: XBRL DOCUMENT v3.24.1.u1
REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATION
 3 Months Ended
Mar. 31, 2024
Concentration Risk And Geographic Information [Abstract]  
REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATION REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATION
The Company operates in one business segment, which focuses on the development and commercialization of innovative therapies for people with serious and life-threatening rare diseases and medical conditions.
The following table presents Total Revenues and disaggregates Net Product Revenues by product.
Three Months Ended
March 31,
20242023
VIMIZIM$192,520 $189,192 
VOXZOGO152,889 87,836 
NAGLAZYME105,629 123,021 
PALYNZIQ75,709 62,352 
BRINEURA39,047 39,144 
KUVAN35,910 50,478 
ALDURAZYME35,262 34,403 
ROCTAVIAN849 — 
Total net product revenues637,815 586,426 
Royalty and other revenues11,018 9,989 
Total revenues$648,833 $596,415 
The Company considers there to be revenue concentration risks for regions where Net Product Revenues exceed 10% of consolidated Net Product Revenues. The concentration of the Company’s Net Product Revenues within the regions below may have a material adverse effect on the Company’s revenues and results of operations if sales in the respective regions experience difficulties. The table below disaggregates total Net Product Revenues by geographic region, which is based on patient location for the Company's commercial products sold directly by the Company, except for ALDURAZYME, which is marketed and sold exclusively by Sanofi worldwide.
Three Months Ended
March 31,
20242023
United States$192,999 $166,761 
Europe195,748 160,692 
Latin America78,594 67,748 
Middle East57,075 91,642 
Rest of world78,137 65,180 
Total net product revenues marketed by the Company602,553 552,023 
ALDURAZYME net product revenues marketed by Sanofi35,262 34,403 
Total net product revenues$637,815 $586,426 
The following table illustrates the percentage of the Company’s total Net Product Revenues attributed to the Company’s largest customers for the periods presented. 
Three Months Ended
March 31,
20242023
Customer A14 %14 %
Customer B11 %10 %
Total25 %24 %
On a consolidated basis, two customers accounted for 15% and 11% of the Company’s March 31, 2024 accounts receivable balance, respectively, compared to December 31, 2023, when two customers accounted for 15% and 12% of the accounts receivable balance, respectively. As of March 31, 2024, and December 31, 2023, the accounts receivable balance for Sanofi included $63.1 million and $63.4 million, respectively, of unbilled accounts receivable, which becomes payable to the Company when the product is sold through by Sanofi. The Company does not require collateral from its customers, but does perform periodic credit evaluations of its customers’ financial condition and requires prepayments in certain circumstances.
The Company is mindful that conditions in the current macroeconomic environment, such as inflation, changes in interest and foreign currency exchange rates, natural disasters and supply chain disruptions, could affect the Company’s ability to achieve its goals. In addition, the Company sells its products in countries that face economic volatility and weakness. Although the Company has historically collected receivables from customers in certain countries, sustained weakness or further deterioration of the local economies and currencies may cause customers in those countries to delay payment or be unable to pay for the Company’s products. The Company believes that the allowances for doubtful accounts related to these countries, if any, are adequate based on its analysis of the specific business circumstances and expectations of collection for each of the underlying accounts in these countries. The Company will continue to monitor these conditions and will attempt to adjust its business processes, as appropriate, to mitigate macroeconomic risks to its business.